이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

다양한 암 환자 그룹을 위한 유전자 검사에 관한 새로운 교육 자료 개발 (IMAGINE)

2026년 10월 1일 업데이트: Memorial Sloan Kettering Cancer Center

IMAGINE: 모든 사람을 위한 유전 정보에 대한 접근 개선 - 유전암에 대한 언어적, 문화적으로 적절한 주류화 모델의 전향적 시험 다양한 암 환자를 대상으로 한 다유전자 패널 테스트

Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder. Genetic tests use a sample of blood, hair, skin, or other tissue, and they can look at one gene or multiple genes at the same time. Genetic testing may change the options for treating people with certain types of cancer. For example, some medications are more helpful for the treatment of cancer in people with certain gene changes (mutations).

The researchers are doing this study to develop new educational materials about genetic testing for people who speak different languages and have diverse cultural and educational backgrounds. During the study, the staff will interview participants with diverse cultural and educational backgrounds and ask them to review a sample of the educational materials that have been developed so far. Participants will give their opinions on these materials, and the researchers will use participants' feedback to improve the materials.

연구 개요

상세 설명

The objective of this proposal is to develop, test and evaluate a mainstreaming (LCAM) model for hereditary cancer multigene panel testing (MGPT) among many different types of cancer patients. The central hypothesis is that this LCAM genetic testing model will lead to better patient decision-making, psychosocial, and behavioral outcomes than a traditional model of genetic services represented by our standard-of-care arm. In Phase 1, the researchers will first conduct formative research including transcreation and cognitive interviewing to adapt our existing educational materials (brochure and video) and clinical communication materials (clinic visit summary and family dissemination messaging) for the LCAM model to be useful for patients of many different backgrounds. In Phase 2, the researchers will conduct a randomized clinical trial (RCT) to test and evaluate effects of the LCAM model for hereditary cancer MGPT as compared to standard-of-care among the patients treated at local community hospitals. Patients diagnosed with breast, colorectal, ovarian, pancreatic, or prostate cancer will be offered hereditary cancer MGPT through either: i) standard-of-care wherein in-depth pre-test and post-test genetic counseling are provided via telegenetics (videoconferencing), or ii) LCAM intervention wherein patients receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic "literacy screener" and adapted clinical communication materials. Participants will be followed prospectively and will complete assessments consisting of validated and investigator-designed measures. Phase 2 primary outcomes include genetic test decision satisfaction and genetic counseling satisfaction. Secondary outcomes include additional decision-making, psychosocial, and behavioral outcomes.

For Phase 2, participants will be recruited from our partnering sites, which include Kings County Hospital Center, Queens Cancer Center, Jamaica Hospital Medical Center, and the MSK Ralph Lauren Center for Cancer Care as well via referrals from underserved community sites through the MSK RLCCC network. Study staff will identify eligible patients from review of clinic lists and patient medical records, and will also receive direct study referrals from clinicians located at the partnering sites. Study staff will approach eligible patients in order to describe the study, screen them for eligibility (including assessing language proficiency via self-report and prior experience with cancer genetic counseling/testing), and obtain informed consent and collect their contact information.

연구 유형

중재적

등록 (추정된)

445

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Jennifer Hay, PhD
  • 전화번호: 646-888-0039

연구 연락처 백업

  • 이름: Jada Hamilton, PhD, MPH
  • 전화번호: 646-888-0049
  • 이메일: hamiltoj@mskcc.org

연구 장소

    • New York
      • Brooklyn, New York, 미국, 11203
        • 모병
        • Kings County Hopsital Center
        • 연락하다:
          • Jason Gonsky, MD
          • 전화번호: (718) 245-2847
      • Jamaica, New York, 미국, 11432
        • 모병
        • Queens Cancer Center of Queens Hospital
        • 연락하다:
          • Linda Bulone, RN, OCN, CCRC
          • 전화번호: (718) 883-2958
      • New York, New York, 미국, 10035
        • 모병
        • Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)
        • 연락하다:
          • Jada Hamilton, PhD, MPH
          • 전화번호: 646-888-0049
      • Richmond Hill, New York, 미국, 11418
        • 모병
        • Jamaica Hospital Medical Center (Data Collection Only)
        • 연락하다:
          • Rosa Nouvini, MD
          • 전화번호: (718) 206-6000

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

Phase 1

  • Age ≥ 18 years as per self-report
  • Current or previous diagnosis of breast, ovarian, pancreatic, or prostate cancer as per self-report
  • Self-identification as Black, Latino, and/or neither Black nor Latino (i.e.,non-Latino, Non black)
  • Fluency in English, Haitian Creole, or Spanish as per self-report (for Spanish, we will attempt to recruit a cohort representing a variety of regions where Spanish is spoken, as informed by current data from participating sites, to achieve neutrality in the language) Fluency is defined as an answer of "well" or "very well" on the screening questions for spoken and reading ability.

Phase 2:

  • Age ≥ 18 years as per the medical record and/or clinician referral

  • Current or previous diagnosis of breast, colorectal, ovarian, pancreatic, or prostate cancer meeting at least one of the applicable criteria for the cancer type as per the medical record and/or clinician referral:

  • Breast cancer criteria:

    • any diagnosis age 65 or younger;
    • diagnosis of triple negative breast cancer at any age;
    • multiple primary breast cancers at any age;
    • under consideration for PARP therapy;
    • any family history (1st, 2nd, or 3rd degree relatives) of ovarian or pancreas cancer, or 1 relative with breast cancer who meets the above criteria, or 2 relatives with breast cancer at any age; or clinician discretion)
  • colorectal cancer

  • Ovarian cancer criteria:

  • invasive ovarian cancer

  • Pancreatic cancer criteria:

  • pancreatic adenocarcinoma

  • Prostate cancer criteria:

    • castrate-resistant, metastatic prostate cancer;
    • high-risk prostate cancer (pending pathology definition)
  • Fluency in English, Haitian Creole, or Spanish as per self-report. Fluency is defined as an answer of "well" or "very well" on the screening questions for spoken ability

  • No prior cancer genetic counseling or germline testing for cancer risk as per self-report clinician's note, and/or no clinical documentation

Exclusion Criteria:

Phase 1:

  • Individuals of impaired decision-making capacity as per a clinician's or consenting professional's judgment.
  • Subjects who indicate level of fluency as "not at all" or "not well".

Phase 2:

  • Individuals of impaired decision-making capacity as per a clinician's or consenting professional's judgment.
  • Subjects who indicate level of fluency as "not at all" or "not well".

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 건강 서비스 연구
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cognitive interview intervention for Phase 1

There is no treatment or intervention for Phase 1 of this study. Participants will be asked to participate in a cognitive interview.

This section will be amended to include the Phase 2 intervention information once the Phase 1 portion of the study is complete. The Phase 1 materials developed, and results obtained, will directly be part of and inform the intervention for Phase 2.Phase 2: participants will be randomized to the standard-of-care arm or the LCAM intervention arm.

Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.

활성 비교기: Standard of care (Phase II only randomization)

Participants will receive in-depth pre-test and post-test genetic counseling provided via telegenetics

Participants will receive in-depth pre-test and post-test genetic counseling provided via telegenetics

활성 비교기: LCAM Intervention (Phase II only randomization)

Participants will receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic "literacy screener" and adapted clinical communication materials.

Participants will receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic "literacy screener" and adapted clinical communication materials.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of patients who complete the cognitive interview (Phase I)
기간: 1 year

the number of patients who complete the cognitive interview

1 year
Genetic test decision (Phase II) satisfaction
기간: 6 months

is measured with the validated Satisfaction with Decisions scale.

6 months
Genetic counseling satisfaction (Phase II)
기간: 6 months

is measured with the validated Genetic Counseling Satisfaction scale

6 months

2차 결과 측정

결과 측정
측정값 설명
기간
Test uptake (Phase II)
기간: 6 months

the number of patients who complete multigene panel testing

6 months
Knowledge (Phase II)
기간: 6 months

measured with items from the validated KnowGene scale (scores range from 0 to 6, higher scores indicate greater knowledge)

6 months
Empowerment (Phase II)
기간: 6 months

measured with the validated Genomics Outcome Scale (scores range from 6 to 30, higher scores indicate greater empowerment)

6 months
Distress (Phase II)
기간: 6 months

measured with the validated Hospital Anxiety and Depression Scale (total scale scores range from 0 to 42, higher scores indicate greater distress)

6 months
Concerns about genetic testing (Phase II)
기간: 6 months

measured with the validated Multidimensional Impact of Cancer Risk Assessment questionnaire (total scale scores range from 0 to 95, higher scores indicate greater concerns about genetic testing)

6 months
Family communication (Phase II)
기간: 6 months

measured with investigator-designed items

6 months
Family cascade testing (Phase II)
기간: 6 months

the number of first-degree relatives who complete genetic testing

6 months
Intentions to adopt risk management behaviors (Phase II)
기간: 6 months

measured with items derived from the Behavioral Risk Factor Surveillance System and National Health Interview Survey

6 months
Long term engagement and understanding (Phase II)
기간: 6 months

measured with investigator-designed items

6 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Jada Hamilton, PhD, MPH, Memorial Sloan Kettering Cancer Center

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 11월 16일

기본 완료 (추정된)

2027년 8월 31일

연구 완료 (추정된)

2027년 8월 31일

연구 등록 날짜

최초 제출

2021년 2월 8일

QC 기준을 충족하는 최초 제출

2021년 2월 8일

처음 게시됨 (실제)

2021년 2월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 1일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다